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Abstract
Background The potential role of ω-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation during pregnancy 
on subsequent risk of obesity outcomes in the offspring is not clear and there is a need to synthesise this evidence.
Objective A systematic review and meta-analysis of randomised controlled trials (RCTs), including the most recent studies, 
was conducted to assess the effectiveness of ω-3 LCPUFA interventions during pregnancy on obesity measures, e.g. BMI, 
body weight, fat mass in offspring.
Methods Included RCTs had a minimum of 1-month follow-up post-partum. The search included CENTRAL, MEDLINE, 
SCOPUS, WHO’s International Clinical Trials Reg., E-theses and Web of Science databases. Study quality was evaluated 
using the Cochrane Collaboration’s risk of bias tool.
Results Eleven RCTs, from ten unique trials, (3644 children) examined the effectiveness of ω-3 LCPUFA maternal supple-
mentation during pregnancy on the development of obesity outcomes in offspring. There were heterogeneities between the 
trials in terms of their sample, type and duration of intervention and follow-up. Pooled estimates did not show an association 
between prenatal intake of fatty acids and obesity measures in offspring.
Conclusion These results indicate that maternal supplementation with ω-3 LCPUFA during pregnancy does not have a ben-
eficial effect on obesity risk. Due to the high heterogeneity between studies along with small sample sizes and high rates of 
attrition, the effects of ω-3 LCPUFA supplementation during pregnancy for prevention of childhood obesity in the long-term 
remains unclear. Large high-quality RCTs are needed that are designed specifically to examine the effect of prenatal intake 
of fatty acids for prevention of childhood obesity. There is also a need to determine specific sub-groups in the population 
that might get a greater benefit and whether different ω-3 LCPUFA, i.e. eicosapentaenoic (EPA) vs. docosahexanoic (DHA) 
acids might potentially have different effects.
Keywords Systematic review · Meta-analysis · Fatty acids · Fish oil · N-3 LCPUFA · Obesity · Childhood obesity · 
Adiposity · Body composition · Growth · Infant’s growth
Introduction
The high prevalence of childhood obesity is a serious public 
health issue and has been reported as a potential risk factor 
for a range of morbidities and medical conditions that occur 
later in life [1–4].
The very early days of fetal development, representing a 
period of substantial developmental plasticity, are thought 
to impact on health in the life course [5]. The developmental 
origins of health and disease theory proposes that events/
exposures during this period are a key determinant of the 
susceptibility to many chronic diseases, including meta-
bolic disorders and obesity [6]. It is well documented that 
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the foetus responds to external stimuli in utero and envi-
ronmental factors such as maternal diet could have effects 
later in life [7–10]. In this context, interventions that target 
the nutritional adequacy of women’s diet during pregnancy 
could provide a unique opportunity for early prevention of 
chronic diseases including obesity.
Over recent decades, the dominance of ω-6 fatty acids in 
diets, particularly in industrialised countries, has led to sug-
gestions that there maybe an association between the ratio 
of ω-6/ω-3 long chain polyunsaturated fatty acid (LCPUFA) 
and adipose tissue development during the critical early 
phases of life [11–13]. While ω-6 LCPUFA may have a stim-
ulatory effect on fat cell development, there is evidence to 
suggest that ω-3 LCPUFA (DHA and EPA) have anti-obesity 
effects by decreasing lipid synthesis in cells [14–16]. Human 
adipose tissue starts to develop in the second trimester of 
pregnancy [17]. Fat cells acquired at an early stage in life 
may determine the level of fully differentiated adipocytes 
later in life, with only approximately 10% of fat cells being 
replaced across all ages and at all levels of BMI [18]. Collec-
tively this evidence suggests that maternal intake of ω-3 fatty 
acids during pregnancy might help to reduce susceptibility 
to obesity later in life.
The effect of exposure to an increased supply of ω-3 LCP-
UFA in utero on body composition in the child has been 
examined in a number of RCTs. However, these have pro-
duced conflicting results. This systematic review and meta-
analysis aimed to summarise the existing evidence from 
these RCTs, providing an update to the earlier systematic 
reviews on this topic [19–24] to include recently published 
trials.
Methods
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials (RCT, including cluster 
randomised controlled trials and quasi-randomised con-
trolled trials) with a minimum follow-up of 1 month post-
natally were included. The review considered studies which 
reported body composition data and used maternal ω-3 
LCPUFA supplementation. No language or country restric-
tions were applied.
Types of participants
Pregnant women and their offspring were considered as the 
target group for this systematic review. High-risk popula-
tions were not excluded.
Types of interventions
Trials were included that used ω-3 LCPUFA supplementa-
tion during pregnancy, irrespective of dose, formulation or 
mode of delivery and composition, e.g. oil, tablet. Trials 
were also included if the intervention(s) had been extended 
after pregnancy either during breast-feeding or directly to 
the infants or both.
Types of outcomes measures
Trials were included if they had reported measures of obe-
sity or growth in the offspring, either as a primary or second-
ary endpoint. Obesity measures were defined as: body mass 
index (BMI), skin-fold thickness (SFT), obesity, overweight 
and fat mass. Growth measures (weight, height/length) were 
considered as secondary outcomes in the review. For trials 
in which obesity measures were assessed at more than one 
time point, only the results of the latest follow-up time point 
was included in the meta-analyses.
Search strategy for identification of studies
A comprehensive search strategy, including all relevant syn-
onyms for the main concepts, was developed covering the 
main bibliographic databases. Trials were identified through 
systematic searches within three main electronic databases, 
as advised by the Cochrane collaboration [25]:
(a) Cochrane Library (current issue) including:
• Cochrane Database of Systematic Reviews (CDSR)
• CENTRAL (trials)
• DARE
(b) MEDLINE (EBSCOhost)
(c) SCOPUS
When searching MEDLINE, the subject-specific terms 
were combined with the Cochrane Highly Sensitive Search 
Strategy for identifying randomised trials in MEDLINE: 
sensitivity-maximising version [25]. We adapted the pre-
liminary search strategy for MEDLINE (EBSCOhost) for 
use in the other databases when relevant. The last search for 
literature was conducted in January 2018.
The clinical trials registry and WHO platform were 
searched for ongoing and recently completed trials. Confer-
ence proceedings were identified through the ISI Web of Sci-
ence and, for retrieving theses the British Library E-Theses 
Online Service was searched. No language or publication 
status restrictions were imposed. References of included 
studies were crosschecked for additional studies.
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Data collection and analysis
Selection of studies
The main reviewer (MV) along with the second reviewer 
(HM) screened all the search results against the eligibility 
criteria and all those which were clearly irrelevant were 
excluded from further consideration. Thereafter, a tailored 
eligibility form was used by MV to appraise the retrieved 
studies, abstract and full text for relevance against the 
full inclusion criteria. Where there was uncertainty about 
inclusion of a particular study, this was discussed within 
the review team (MV, HM, TD) and a consensus was 
reached about the study eligibility. All the included stud-
ies were discussed and approved by the review team.
Data extraction and management
MV extracted the data using a tailored data extraction form 
in EPPI Reviewer. Detailed information on study char-
acteristics were recorded. Throughout the data extraction 
process, any disagreements about the interventions and 
outcomes were discussed and resolved within the review 
team. There was no blinding of the authors’ name, insti-
tutions, journals or the outcomes of the trials during the 
process. The extracted data were double checked by a sec-
ond reviewer (HM) for accuracy against the trial reports.
Assessment of risk of bias in included studies
The risk of bias tool described in the Cochrane Hand-
book for Systematic Reviews for Interventions was used 
to appraise the studies [26].
Measurement of treatment effect
Dichotomous data were analysed as risk ratios or relative 
risk (RR) with 95% CI and continuous data as mean differ-
ence or standardised mean difference, with 95% CI.
Unit of analysis issues
In trials with more than one intervention arm, multiple 
pairwise comparisons of intervention groups vs. compara-
tor were avoided. Therefore, data from different interven-
tion arms were pooled for an overall comparison with the 
control or placebo arm. The weight assigned to the control 
group was considered as the total number of participants in 
the comparator group vs. the total number of participants 
in the combined intervention arms [27].
Dealing with missing data
All the relevant reported information for the number of miss-
ing participants was extracted and if undocumented, this was 
incorporated into the assessment of risk of bias. No imputed 
techniques were used for retrieving missing data.
Assessment of heterogeneity
We used visual inspection of forest plots and the χ2 test 
to measure statistical heterogeneity between effect sizes 
of included studies. I2 statistics were used to quantify the 
amount of possible variability in effect estimates that is due 
to heterogeneity rather than chance (I2 < 25% low heteroge-
neity, ≥ 26% I2 < 74% moderate heterogeneity, I2 ≥ 75% high 
heterogeneity). Where there were heterogeneities between 
trials, a random effect model was used and meta-analysis 
reported if a moderate heterogeneity was found [25].
Assessment of reporting biases
Every effort was made to identify unpublished studies 
through searching abstracts and ongoing trials databases. 
Publication bias was not assessed due to the small number 
of included studies [28].
Data synthesis
We used EPPI Reviewer version 4.4.3.0. for conducting 
meta-analyses. Dichotomous data (events) and the number 
of participants were entered. We reported relative risk to 
describe the study effect [29].
Subgroup analysis and investigation 
of heterogeneity
Where possible, sub-group analyses were performed for the 
control group and duration of follow-up.
Sensitivity analysis
We did not conduct any sensitivity analysis because of the 
small number of studies that contributed to meta-analyses.
Results
Electronic searches yielded a total of 2484 results (Fig. 1). 
After removal of duplicates and non-relevant studies, the 
remaining 86 full text papers were assessed against the 
 European Journal of Nutrition
1 3
eligibility criteria for this systematic review. Eleven pub-
lications from ten unique RCTs were included in the final 
analyses, including a total of 3644 children. In the case of 
one trial [53], both the reports of an earlier [52] as well as 
latest follow-up data [54] were included. This was because 
the earlier report [52] included 1531 of children from the 
recruited sample in the original trial [53] whereas the later 
follow-up at 7 years [54] only included a sub-sample (a small 
percentage of pregnant women that were initially recruited 
at randomisation and assessed body composition outcomes 
in children using BOD POD and Bioelectrical Impedance 
Spectroscopy (BIS) methods). The characteristics of the 
included trials, their companion papers and study popula-
tion are presented in Table 1. One trial was multi-centre 
(Germany, Hungry and Spain), four studies were conducted 
in Australia and Germany (two each) and the rest in Norway, 
Denmark, Mexico, the United States and Iran.
Study design
All the included trials were parallel RCTs and most trials 
had two parallel groups while two had three parallel groups, 
either as intervention or control. The study by Campoy et al. 
[35] defined interventions as modified fish oil plus vitamin 
and mineral, fish oil plus 5-methyltetrahydrofolic (MTHF) 
and 5-MTHF only. In this systematic review, we have only 
considered modified fish oil component plus vitamin and 
mineral as the intervention arm compared to placebo. Rytter 
and colleagues [39] also had two control groups, ‘olive oil’ 
or ‘no oil’. Olive oil was used as the comparator for meta-
analyses in this systematic review. In addition, the nature of 
the control group (standard diet) in the study by Brei et al. 
[47] was different from other trials and, therefore, this study 
was included in the sub-group analyses.
It is important to note that most of the trials were primar-
ily designed to investigate other outcomes in children such 
as neurological development, maternal insulin sensitivity; 
and growth measures in the offspring are also reported as 
secondary end-points [31, 34, 35, 39, 41, 44, 52, 54, 55]. 
Only two trials [47, 56] were originally designed to evaluate 
the effectiveness of prenatal n-3 LCPUFA supplementation 
on infant’s body composition. The study by Brei et al. [47] 
was an open label trial and applied a combined intervention 
approach of fish oil capsules and arachidonic acid-balanced 
diet (ratio of ω-6/ω-3) during pregnancy. This study also 
had a high non-participation rate at the 5 years follow-up. 
In the study by Ostadrahimi et al. [56], the primary out-
come was defined as infants’ neurodevelopment status 
Fig. 1  Study flow diagram, 
following preferred reporting 
items for systematic reviews 
and meta-analyses (PRISMA) 
criteria
Records identified through database 
searches (n=2482)
Medline: n=1016, 
SCOPUS: n=1193 
Cochrane (trials only): n=273 
Additional records identified through 
other sources
(n=2)
Titles and abstracts screened
(2484)
Abstracts selected for further screening 
(n=547)
Duplicates removed
(n=1937)
Citations included: 28
Primary articles included in quantitative 
syntheses (meta-analyses): n=11
Companion papers: 17
Abstracts excluded (n=461):
Reviews/different 
intervention /different 
outcome/after birth
Full-text articles assessed for eligibility
(n=86)
Full-text papers excluded 
(n=58)
Non-randomised: 23
Different outcome: 35
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and anthropometric measures were reported as secondary 
end-points.
Participants and sample sizes
One trial was conducted in atopic women [34] and another 
in women who were obese or had a history of gestational 
diabetes [55]. The remainder of the trials involved healthy 
pregnant women with non-complicated pregnancies. Studies 
varied in their sample size at randomisation from 72 [55] to 
1660 [52] pregnant women.
Intervention
With the exception of one study that used algal DHA [44], 
all other studies used either DHA alone or a combination 
of EPA and DHA together. In the study by Campoy et al. 
[35] vitamin and mineral supplements were also used along 
with the fatty acid component. Furthermore, Brei et al. [47] 
provided women with ω-3 LCPUFA intervention as well as 
nutritional counseling, focused on reducing the consump-
tion of n-6 fatty acid (AA) to a moderate level of intake 
(90 mg AA per day). Six trials supplemented women dur-
ing pregnancy only and in the case of four trials [32, 35, 47, 
56] the intervention was continued postnatally with various 
durations.
Compliance with the intervention was assessed by a vari-
ety of methods, including the number of fatty acids capsules 
ingested, divided by the number the participant should have 
ingested multiplied by 100; standardised questionnaires at 
gestation; the percentage of the total number of capsules 
expected to be consumed; and measuring fatty acids levels 
in erythrocytes at 30 and 37 gestational week, and 6 weeks 
postnatally. Four studies did not report the method of meas-
uring adherence to the intervention [32, 41, 47, 56].
Reported obesity outcomes and follow‑up duration
Anthropometric measurements were conducted using stand-
ardised references, e.g. WHO reference ranges (including 
BMI-Z) and by means of standard tools. The definition 
and diagnosis method for each outcome included in meta-
analyses is presented in Table 2. The duration of follow-up 
in trials ranged from 6 months [56] to 19 years [39]. The 
most frequently reported obesity measures were BMI and 
the most reported growth measures were weight and height.
Also, while the trial by Wood [54] reported longer-
term follow-up at 7 years from the original study [53], 
data from the earlier follow-up at 5 years were included in 
meta-analyses. This was because only 30.3% of the origi-
nal sample recruited in the Adelaide centres (504 of 1660 
pregnant women that were not participating in the neu-
rodevelopmental study) were eligible to participate in the Ta
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Table 2  Definition of obesity measures included in the meta-analyses and their measurement in individual studies
Studies Measurement
Helland (2008) [31], 7 years follow-up
 BMI Not defined
 Weight Not defined
 Height Not defined
Dunstan (2008) [34], 2.5 years follow-up
 Weight Not defined
 Height Not defined
Campoy (2011) [35], 6.5 years follow-up
 BMI Not defined
Rytter (2011) [39], 19 years follow-up
BMI Not defined
Bergmann (2012) [41], 6 years follow-up
 BMI Length (height) and weight were measured using Harpenden measuring boards, small measuring 
tapes and calibrated Seca balances and BMI was calculated accordingly
 BMI-Z BMIs of children from birth to 6 years were standardised with age-specific means of the World 
Health Organisation (WHO) multi-centre growth reference study
 Weight Using calibrated Seca balances
 Height Harpenden measuring boards and small measuring tapes
 Sum of SFT Using a Holtain caliper at the midtricipital, the subscapular and the suprailiac measuring point
Gonzalez-Casanova (2015) [44], 5 years 
follow-up
 BMI-Z BMI was computed by calculating age at measurement from the date of birth and then converted 
to age-specific Z scores using the 2006 WHO reference standards
 Weight Using a Tanita scale to the nearest 10 g
 Height Using a Seca stadiometer to the nearest 1 mm
Brei (2016) [47], 5 years follow-up
 Weight Using a standard flat scale (Seca Clara), to the nearest 100 g with the child in a standing position
 Height Using a stadiometer, to the nearest 0.5 cm with the child in a standing position
 Sum of SFT SFTs were measured in triplicate with the use of a Holtain caliper (Holtain Ltd.) at 4 different 
body sites on the left body axis (triceps, biceps, sub- scapular, and suprailiac), at the study 
center or at the family’s home. The mean of the 3 measurements was used for the SFT value, 
and the sum of the 4 SFTs was calculated
 Body fat (%) Using predictive skinfold regression equations according to Weststrate and Deurenberg
 Fat mass (kg) Using predictive skinfold regression equations according to Weststrate and Deurenberg
Muhlhausler (2016) [52], 5 years follow-up
 BMI Weight using electronic scales (without shoes and in underwear to the nearest 100 g); height 
using a stadiometer without shoes and BMI was calculated accordingly
 BMI-Zs The BMI measures for each child were compared with standardized reference charts for the 
child’s age and sex to calculate their Z scores
 Weight As above
 Height As above
 Body fat (%) Using the equation as: [fat-free mass − body weight|body weight] × 100
 Fat mass (kg) Using bioelectrical impedance spectroscopy
Foster (2017) [55], 4 years follow-up
 BMI-Z Each child was weighed on a digital scale with no shoes and measured to the nearest 0.1 kg with 
the procedure repeated. The two weight measurements were required to be within 0.2 kg for 
accuracy and precision. Standing height was measured in cm on a stadiometer with a fixed ver-
tical bar and an adjustable headpiece with shoes removed. Height measurement was recorded 
to the nearest 0.1 cm, and then the process was repeated. The two height measurements were 
required to be within 0.2 cm for accuracy and precision. Z scores were calculated using the 
Centers for Disease Control and Prevention (CDC) reference data
Ostadrahimi (2017) [57], 6 months follow-up
 Weight Using a lever scale with a precision of 0.1 kg (Seca, Germany)
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body composition follow-up study at 7 years [54]. Of the 
504 women invited only 252 [50%] consented to participate 
and therefore, the sample may not be representative of the 
original recruited women. The results from this study [49] 
are described narratively.
Quality of RCTs
The methodological quality of the included trials varied as 
shown in Fig. 2. Six trials had a low risk of bias in both their 
random sequence generation and allocation concealment 
(55%) in each domain. Blinding of both participants/staff 
and outcome assessment were deemed as low risk of bias 
in four and seven trials, respectively. Over half of the trials 
were rated as high risk of bias for the completeness of data 
(64%) because of high attrition bias. All trials were deemed 
to have a low risk of bias for the reported outcomes and 
five trials were rated as unclear for other potential sources 
of bias.
Pooled effect of interventions
The definition of the outcomes in each study, as included 
in meta-analyses, and their diagnosis method are presented 
in Table 2.
BMI as outcome measure
Five trials reported BMI in children and statistically, the 
studies were largely homogenous (χ2 = 1.57, P = 0.81, 
I2 = 0%). The pooled results did not show an association 
between maternal ω-3 LCPUFA intervention during preg-
nancy and BMI in the offspring (mean difference (SMD) 
− 0.001, 95% CI − 0.08, 0.08; 2051 children) (Fig. 3).
A sub-group analysis was also conducted including only 
the studies with comparable duration of follow-up [32, 35, 
41]. The results did not yield any significant change (SMD 
0.001, 95% CI − 0.089, 0.92; 1871 children) (Forest plot 
not shown).
Table 2  (continued)
Studies Measurement
 Height Using a stadiometer table accurate to 0.1 cm in the supine position without shoes and hats
Short Title Random Sequence 
Generation
Allocation 
Concealment
Double 
Blinding
Blinding of Outcome 
Assessment
Incomplete 
Outcome Data
Selective Outcome 
Reporting
Other Sources 
of Bias
Bergmann (2012) + ? ? + + + ?
Brei (2016) + ? - - - + ?
Campoy (2011) ? - + ? - + ?
Dunstan (2008) ? + + + + + +
Foster 2017 ? ? ? ? + + +
Gonzalez-Casanova (2015) ? + + + - + +
Helland (2008) + ? ? ? - + +
Muhlhausler (2016) + + ? + - + ?
Ostadrahimi 2017 + + + + + + +
Rytter (2011) ? + - + - + +
Wood (2017) + + ? + - + ?
Random Sequence Generation 55% 45%
Allocation Concealment 55% 36% 9%
Double Blinding 36% 46% 18%
Blinding of Outcome Assessment 64% 27% 9%
Incomplete Outcome Data 36% 64%
Selective Outcome Reporting 100%
Other Sources of Bias 55% 45%
Low risk of bias: Unclear risk of bias: High risk of bias: 
Fig. 2  Risk of bias assessment figure in the included trials
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BMI‑Z as outcome measure
The outcome was reported in four trials and moderate 
heterogeneity was observed between the trials (χ2 = 7.26; 
P = 0.06; I2 = 58.7%). Meta-analysis of these trials did not 
show an association between maternal ω-3 LCPUFA inter-
vention during pregnancy and BMI-Z in offspring (SMD 
0.082, 95% CI − 0.077, 0.24; 2511 children) (Fig. 4).
The study by Foster [55] recruited a high-risk sample of 
pregnant women, with obesity or a history of gestational 
diabetes and excluding this study from meta-analysis there 
was no heterogeneity between trials (I2 = 0%). However the 
pooled results did not significantly change (SMD 0.0178, 
95% CI − 0.0616, 0.0972) (Forest plot not shown).
Sum of SFT as outcome measure
Skinfold thickness was reported in three trials and the pooled 
results showed a high level of heterogeneity between trials 
(χ2 = 38.6, P = 4.06, I2 = 94.8%). The study by Foster [55] 
only reported a single measure of arm SFT, as opposed to 
the sum of SFT for 3–4 body points reported in other tri-
als, and given that the study was also conducted in high-
risk pregnant women (obese/history of gestational diabe-
tes), we pooled the results excluding this study from the 
Fig. 3  Forest plot for prenatal 
intake of fatty acid vs. placebo 
for BMI
Heterogeneity: Q = 1.57; df = 4; p = 0.814; I-squared = 0%; tau-squared = 0
Fixed effect model: -0.00117 (-0.0882, 0.0858)
Outcome: BMI Fatty acid Mean (SD) Placebo Mean (SD)
Bergmann (n=41/74) 15.7 (1.5) 15.5 (1.3)
Campoy (n=37/45) 17.23 (2.92) 16.82 (2.30)
Helland (n=82/61) 16.4 (1.7) 16.3 (1.7)
Muhlhausler (770/761) 16.19 (1.61) 16.2 (1.73)
Rytter (n=108/72) 22.5 (3.5) 22.6 (3.8)
Subtotal: (n=1,038/1,013)
Fig. 4  Forest plot for prenatal 
intake of fatty acid vs. placebo 
for BMI-Z
Heterogeneity: Q=7.26; df = 3; p=0.064; I-squared = 58.7%; tau-squared= 0.0132
Random effects model: 0.0826 (-0.0773, 0.242)
Outcome: BMI-Z Fatty acid Mean (SD) Placebo Mean (SD)
Bergmann (n=41/74) 1.02 (0.09) 1.01 (0.08)
Foster (n=34/29) 1.24 (0.42) 0.92 (0.47)
Gonzalez-Casanova (n=403/399) 0.1 (1.1) 0.1 (1.1)
Muhlhausler (770/761) 0.56 (0.97) 0.54 (1.03)
Subtotal: (n=1,248/1,263)
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meta-analysis. A moderate level of heterogeneity was found 
between the two trials (χ2 = 2.67; P = 0.10, I2 = 62.6%) and 
the meta-analysis did not show an association between 
maternal ω-3 LCPUFA intervention during pregnancy and 
sum of SFT in the offspring (SMD 0.09, 95% CI − 0.33, 
0.53, 227 children) (Fig. 5).
Body fat (%) and fat mass (kg) as outcome measure
There was no heterogeneity between the two trials reporting 
these outcomes (body fat (%): χ2 = 0.10; P = 0.74, I2 = 0% 
and fat mass: χ2 = 0.24; P = 0.61, I2 = 0%). The meta-anal-
yses did not show an association between maternal ω-3 
LCPUFA intervention during pregnancy and body fat (%) 
(SMD 0.00, 95% CI − 0.09, 0.09; 1641 children) and fat 
mass (kg) (SMD 0.01, 95% CI − 0.08, 0.10; 1641 children) 
in the offspring (Figs. 6, 7).
Weight as outcome measure
The outcome was reported in six trials and there was no 
heterogeneity between studies (χ2 = 2.08; P = 0.83, I2 = 0%). 
The results of meta-analysis did not show an association 
between maternal ω-3 LCPUFA intervention during preg-
nancy and weight in offspring (SMD 1.01, 95% CI − 0.056, 
0.091; 2746) (Fig. 8).
A sub-group analysis was also conducted including the 
study conducted by Brei et al. [47], which defined “standard 
diet” as its comparator. The studies were largely homog-
enous (I2 = 0%) and the meta-analysis did not alter the results 
greatly (SMD 0.026, 95% CI − 0.046, 0.099) (Forest plot 
not shown).
In the study by Ostadrahimi children were followed-up 
by 6 months of age [56] and thus, weight was reported as 
a growth measure. Since the study had the shortest follow-
up duration compared to the other included trials, a meta-
analysis was conducted excluding this study and did not alter 
the results (SMD 0.009, 95% CI − 0.0669, 0.0854).
Height as outcome measure
The outcome was reported in six trials and statistically, there 
was no heterogeneity between studies (χ2 = 2.97; P = 0.70, 
I2 = 0%). The results of meta-analysis did not show an 
Fig. 5  Forest plot for prenatal 
intake of fatty acid vs. placebo 
for sum of SFT
Heterogeneity: Q=2.67; df =1; p=0.102; I-squared = 62.6%; tau-squared = 0.062
Random effects model: 0.0968 (-0.339, 0.533)
Outcome: Sum of SFT Fatty acid Mean (SD) Placebo Mean (SD)
Bergmann (n=41/74) 23.2 (7.1) 21.1 (6.1)
Brei (n=57/55) 23.9 (4.7) 24.5 (5.0)
Subtotal: (n=98/129)
Fig. 6  Forest plot for prenatal 
intake of fatty acid vs. placebo 
for body fat (%)
Heterogeneity: Q = 0.103; df = 1; p = 0.749; I-squared = 0%; tau-squared = 0.
Fixed effect model: 0.00169 (-0.095, 0.0984)
Outcome: Body fat (%) Fatty acid Mean (SD) Placebo Mean (SD)
Brei (n=57/55) 17.9 (3.4) 18.1 (3.6)
Muhlhausler (n=770/761) 23.46 (6.82) 23.42 (6.59)
Subtotal: (n=825/816)
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association between maternal ω-3 LCPUFA intervention 
during pregnancy and height in offspring (SMD 0.01, 95% 
CI − 0.06, 0.08; 2746) (Fig. 9).
A sub-group analysis was also conducted including the 
study conducted by Brei et al. [47], which defined “standard 
diet” as its comparator. The studies were largely homog-
enous (I2 = 0%) and the meta-analysis did not alter the results 
greatly (SMD 0.025, 95% CI − 0.046, 0.098) (Forest plot 
not shown).
In the study by Ostadrahimi children were followed-up 
by 6 months of age [56] and thus, height was reported as 
a growth measure. Since the study had the shortest fol-
low-up duration compared to the other included trials, a 
meta-analysis was conducted excluding this study and did 
not alter the results (SMD 0.009, 95% CI − 0.066, 0.086).
Weight Z score and height Z score as outcome 
measures
Two trials by Gonzalez-Casanova et al. [44] and Foster et al. 
[55] reported these outcomes and pooling the results, the 
trials were largely heterogeneous (weight Z score: χ2 = 11; 
P = 0.00, I2 = 90.9% and height Z score: χ2 = 8.61; P = 0.003, 
I2 = 88.4%). There were no associations between maternal 
ω-3 LCPUFA intervention during pregnancy and weight Z 
score and height Z score (Forest plots not shown).
Fig. 7  Forest plot for prenatal 
intake of fatty acid vs. placebo 
for fat mass (kg)
Heterogeneity: Q = 0.247; df = 1; p = 0.619; I-squared = 0%; tau-squared = 0.
Fixed effect model: 0.0121 (-0.0846, 0.109)
Outcome: Fat mass (kg) Fatty acid Mean (SD) Placebo Mean (SD)
Brei (n=57/55) 3.5 (1.1) 3.4 (0.8)
Muhlhausler (n=770/761) 4.75 (1.78) 4.74 (1.85)
Subtotal: (n=825/816)
Fig. 8  Forest plot for prenatal 
intake of fatty acid vs. placebo 
for weight
Heterogeneity: Q = 2.08; df = 5; p = 0.837; I-squared = 0%; tau-squared = 0
Fixed effect model: 0.0174 (-0.0568, 0.0915)
Outcome: Weight Fatty acid Mean (SD) Placebo Mean (SD)
Bergmann (n=41/74) 22.4 (3.1) 22.3 (2.9)
Dunstan (n=33/39) 14.5 (2.0) 14.1 (2.0)
Gonzalez-Casanova (n=369/370) 10.4 (1.1) 10.4 (1.2)
Helland (n=82/61) 26.8 (4.1) 27.0 (4.1)
Muhlhausler (770/761) 19.95 (3.0) 19.87 (3.07)
Ostadrahimi (n=75/71) 7.98 (0.83) 7.84 (0.85)
Subtotal: (n=1,370/1,376)
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Description of the outcomes reported in Wood et al. 
[54] study
This study reported body composition results at 7 years 
follow-up in a sub-sample of total recruited pregnant 
women in Adelaide centres from the original study [53]. 
Body composition measurements were assessed using two 
methods of Air Displacement Plethysmography (BOD 
POD system) and BIS (Table 3). The results suggest that 
the maternal ω-3 LCPUFA intervention during pregnancy 
did not have an influence on childhood anthropometric and 
body composition measures at 7 years follow-up.
Discussion
Eleven RCTs were identified, with a total number of 3644 
children whose mothers started supplementation with ω-3 
LCPUFA during pregnancy and for whom obesity and 
growth measures were followed-up during childhood. 
Trials were heterogeneous for their sample, reported out-
comes and duration of follow-up. Random sequence gen-
eration was deemed to be adequate in six of the included 
trials. Two and five trials were also judged to have a high 
and unclear risk of bias respectively for their performance 
bias and additionally, seven trials had a high attrition bias. 
The findings from this systematic review and meta-analy-
ses did not provide evidence that intake of ω-3 LCPUFA 
during pregnancy could protect against subsequent devel-
opment of a number of childhood obesity outcomes i.e. 
BMI, BMI-Z, weight, height, sum of SFT, body fat (%) 
and fat mass (kg). Overall, the results from this review 
need to be considered with caution because of the large 
heterogeneities observed between studies and also in light 
of the assessment for risk of bias. It is also worth mention-
ing that only two trials [47, 56] were initially designed to 
assess growth and obesity measures in children following 
maternal ω-3 LCPUFA supplementation during pregnancy. 
The results are consistent with those of the meta-analyses; 
neither found a significant difference between the study 
arms for growth measures at 6 months [56] and obesity 
measures at 5 years [47] follow-ups.
Fig. 9  Forest plot for prenatal 
intake of fatty acid vs. placebo 
for height
Heterogeneity: Q = 2.97; df = 5; p = 0.705; I-squared = 0%; tau-squared = 0
Fixed effect model: 0.0133 (-0.0608, 0.0875)
Outcome: Height Fatty acid Mean (SD) Placebo Mean (SD)
Bergmann (n=41/74) 119.2 (5.3) 119.6 (4.6)
Dunstan (n=33/39) 93.8 (3.8) 93.3 (4.6)
Gonzalez-Casanova (n=369/370) 108.3 (4.4) 108.4 (4.5)
Helland (n=82/61) 127.5 (5.5) 128.6 (5.0)
Muhlhausler (770/761) 110.82 (5.06) 110.58 (4.93)
Ostadrahimi (75/71) 67.1 (2.9) 66.9 (2.4)
Subtotal: (n=1,370/1,376)
Table 3  List of the reported clinical outcomes in Wood 2017 study 
[54]
DHA (n = 132)
Mean (SD)
Control (n = 118)
Mean (SD)
P value
BMI 16.48 (2.3) 16.25 (2.56) 0.46
BMI-Z 0.43 (1.07) 0.25 (1.19) 0.22
Weight (kg) 25.18 (4.52) 25.36 (5.31) 0.77
Height (cm) 123.3 (5.11) 124.6 (5.71) 0.07
Body fat (%), BOD 
POD
19.19 (6.89) 19.61 (7.63) 0.58
Body fat (%), BIS 24.22 (7.42) 22.78 (6.68) 0.11
Fat mass (kg), BOD 
POD
5.2 (3.0) 5.12 (3.33) 0.86
Fat mass (kg), BIS 6.28 (2.9) 5.99 (3.18) 0.46
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Overall completeness and applicability of evidence
There was no evidence that ω-3 LCPUFA supplementation 
during pregnancy is effective for prevention of obesity in the 
offspring. The heterogeneity between the trials limited the 
findings and where statistical heterogeneities exist, random 
effect models were used to pool the results. Heterogeneity 
between studies originated from variations in: dosage and 
timing of intervention, comparators, methods for reporting 
the outcome measures across studies, locations/settings and 
the follow-up duration. One study [39] also used DHA, iso-
lated from algae, which may act differently from fish oil 
[58]. It was not possible to conduct stratified analyses for 
the type, dosage and timing of intervention to explore the 
differences due to the relatively small number of trials in 
each group. In addition, although most studies recruited a 
relatively large sample, only a small number of participants 
agreed to participate or could be approached at follow-up 
assessments.
Quality of evidence
Overall, the trials were at moderate to high risk of bias 
(Fig. 2). Randomisation and allocation concealment were 
deemed as unclear for 45% and 36% of included stud-
ies respectively. High loss to follow-up was also a major 
concern where 64% of studies showed high attrition which 
might have largely biased the effect of intervention within 
these trials. In addition, not many studies have reported 
these outcomes in the context of maternal ω-3 LCPUFA 
intervention during pregnancy. Also, measures of obesity 
and growth such as BMI and weight were the most reported 
outcomes in trials and the use of more precise methods for 
measurement of obesity in children such as MRI/ultrasound 
techniques and skinfold thickness, as sum or single measure, 
were reported in only a few trials [41, 47].
Strengths and limitations
This systematic review only included trials in which mater-
nal ω-3 LCPUFA supplementation was commenced dur-
ing pregnancy, thus, crucially, enabling the effect of ω-3 
LCPUFA intervention during pregnancy for prevention of 
childhood obesity to be isolated. Also following an a priori 
published protocol, a comprehensive search strategy allowed 
for a complete coverage of all the relevant literature through 
citation databases, trial registries and conference proceed-
ings with no limitation by language or publication status. 
Moreover, a range of obesity and growth measures were the 
focus of the present review and the most up-to-date results 
from the trials, reported as the longest available follow-up 
data, are included in the meta-analyses. A limitation of the 
review is that sub-group analyses were not conducted as 
planned e.g. duration of intervention, dosage of ω-3 LCP-
UFA because of the limited number of studies that could 
contribute in the meta-analyses.
Consistency with other reviews
Although similar systematic reviews have been conducted, 
they have either examined fatty acid supplementation dur-
ing the prenatal period and also exclusively in breastfeed-
ing [23, 24] or have only examined outcomes at birth [22]. 
Also, other reviews on this topic have narratively described 
the effectiveness of prenatal and postnatal supplementation 
with ω-3 LCPUFA on an infant’s body composition [19–21]. 
The review by Stratakis et al. [23] conducted meta-analyses 
only on BMI for different age groups, although the review 
by Li et al. [24] assessed a wide range of obesity measures 
in children e.g. BMI, weight, sum of SFT.
The main distinction of this systematic review is that it 
examined intake of ω-3 LCPUFA commenced during preg-
nancy and (where applicable) continued postnatally, exam-
ining a wide range of obesity and growth measures. The 
findings from this systematic review did not support the 
hypothesis that maternal ω-3 LCPUFA could protect against 
obesity-related measures in offspring. We have also reported 
methodological shortcomings including number of studies, 
small sample sizes and attrition bias.
Authors’ conclusion
Implications for practice
The results of the current systematic review do not provide 
an evidence for the prevention of obesity in the offspring 
by maternal ω-3 LCPUFA intervention during pregnancy 
when compared with placebo/no treatment. Due to the high 
heterogeneity between studies along with small sample size 
and large attrition at follow-ups, the effects of ω-3 LCPUFA 
supplementation during pregnancy for prevention of child-
hood adiposity in the long-term remains unclear.
Implications for research
While the meta-analyses conducted as part of this systematic 
review did not support the effectiveness of ω-3 LCPUFA 
supplementation during pregnancy and lactation on child-
hood obesity, the heterogeneity in all aspects of the included 
trials makes it difficult to determine whether this is due to 
the lack of an effect, or differences in study design. Hence, 
the effect of maternal ω-3 LCPUFA intervention during 
pregnancy for prevention of childhood obesity need to be 
further investigated in large, high quality RCTs. Further 
research need also to determine specific sub-groups in the 
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population that might get a greater benefit and whether dif-
ferent omega-3 LCPUFA i.e. EPA vs. DHA might poten-
tially have different effects.
Given that only two included studies had been established 
to explicitly examine the effect of maternal ω-3 LCPUFA 
intervention during pregnancy on obesity in offspring, such 
RCTs need to be designed specifically to examine this ques-
tion. Trials should also consider the effect of ω-6/ω-3 ratio in 
the dietary intervention and, rather than increasing ω-3 LC-
PUFA in isolation, to determine the role of the balance of 
fatty acid intake in maternal diet. Using combined methods 
of anthropometric and SFT measurement as well as more 
precise measures such as MRI and ultrasound will also allow 
for more accurate estimation of adipose tissue deposition in 
children.
The optimal timing of ω-3 LCPUFA intervention in preg-
nancy is another key factor that needs to be further investi-
gated. The first appearance of adipocytes in the human foe-
tus occurs in second trimester of pregnancy, between 14 and 
16 weeks of gestation [17]. Further research is required to 
determine the critical window for programming of offspring 
adipose tissue. Baseline level of DHA in pregnant women, 
type and optimal dose of ω-3 LCPUFA, as well as the choice 
of control regimens, are elements that need to be considered 
in further trials. More importantly, additional rigorous strat-
egies are needed to minimise the low participation rate at 
follow-up assessments. Recruiting fewer participants or high 
attrition rates in interventions with ω-3 PUFAs could lead 
to significantly varied findings and thus bias in impact of 
fatty acids, as highlighted in a recent study [59]. Therefore, 
longitudinal studies with adequate sample size and repeated 
measurements are required to provide strong evidence with 
which to determine the effect of ω-3 LCPUFA intake during 
pregnancy on obesity in offspring. Furthermore, the major-
ity of the studies were conducted in developed countries; 
it remains a priority to also understand the effectiveness of 
these interventions for childhood obesity among underre-
ported populations.
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